Board & Advisors

Board of Directors

The Evox Board of Directors is comprised of highly accomplished advisors who each contribute significant expertise in their respective fields. They provide support and guidance to the management team of Evox in achieving its bold vision to positively impact human health by creating novel exosome-based biotherapeutics.

Dr. Antonin “Tony” De Fougerolles

Chief Executive Officer & Director

Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market and in helping build several multi-billion dollar companies from start-up stage including Moderna, Alnylam, and Ablynx.

Paul Carter

Non-Executive Chairman

Paul is a respected leader and board member where he has over the last 25 years held a variety of commercial leadership roles in the biopharmaceutical industry, formally serving as executive vice president, commercial operations of Gilead Sciences. He currently serves on the board of Mallinckrodt Pharmaceuticals PLC and Hutchinson China MediTech Inc.

Martin Andrews

Non-Executive Director

Martin is a respected commercial leader with a strong track record in strategy development and operational delivery most recently as Senior Vice President, Rare Diseases at GlaxoSmithKline, where he oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. He currently serves on the Board of Freeline Therapeutics.

Evan Caplan

Non-Executive Director

Evan is a Principal on the private investment team at OrbiMed, a leading healthcare investment firm.

Alex Hammacher

Non-Executive Director

Alex is Head of Strategy and Corporate Development at Oxford Science Enterprises, the life science and deep tech investment company based in Oxford. He currently serves on the Board of Vaccitech plc.

Amrit Nagpal

Non-Executive Director

Amrit is a Managing Director, Private Investments at Redmile Group, LLC, a healthcare-focused investment firm based in San Francisco and New York.

Sarah Gordon Wild

Non-Executive Director

Sarah has worked on Wall Street for over 15 years and was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She is also currently on the board of Oxford Nanopore and Redx.

Kevin Raidy

Board Observer

Kevin Raidy is the Managing Partner of Cowen Healthcare Investments. He is currently a member of the Board of Directors for several biotechnology companies including Aro Biotherapeutics and Orchard Therapeutics.

Vidu Shanmugarajah

Board Observer

Vidu is a partner on the investing team at GV, based in London. He is also GV’s legal counsel for Europe. Before joining GV in 2015, Vidu’s career spanned law, startups, and investing.

Professor Matthew Wood

Board Observer

Matthew is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at Oxford University and directs the Laboratory of RNA Biology and Neuromuscular Disease.

Scientific Advisory Board

A core component of Evox’s strategy is to support and drive scientific exploration within the exosome space, with a relentless focus on translating scientific discoveries into patient benefits. To this end, Evox has established an extensive network of scientific advisors and collaborators globally.

Dr. Pieter Vader

University Medical Centre Utrecht

Assistant Professor, Department of Clinical Chemistry and Haematology at the University Medical Centre Utrecht. His research is focused on delivery of protein and RNA drugs and has an expertise in exosome engineering.

Professor Robert Langer

Massachusetts Institute of Technology

Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. He is one of the world’s leading scientists and advises Evox on brain and CNS delivery.

Professor Anastasia Khvorova

University of Massachusetts

Professor of Molecular Medicine RNA Therapeutics Institute, University of Massachusetts. She is an expert in RNA therapeutics and performs extensive research on exosomes.

Professor Xandra Breakefield

Harvard Medical School

Professor of Neurology Harvard Medical School. Geneticist, Neurology and Radiology, Massachusetts General Hospital. She conducts research on exosome diagnostics and therapeutics.

Dr. Samir El Andaloussi

Karolinska Institutet

Associate Professor in Biomolecular Medicine at Karolinska Institutet. His research is focused on exosome-based vehicles for macromolecular drug delivery.

Professor Matthew Wood

Oxford University

Professor of Neuroscience and Deputy Head of the Medical Sciences Division at Oxford University and directs the Laboratory of RNA Biology and Neuromuscular Disease.

Strategic Advisors